Focused On-demand Library for Tropomyosin beta chain

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

Beta-tropomyosin; Tropomyosin-2

Alternative UPACC:

P07951; A6NM85; P06468; Q13894; Q53FM4; Q5TCU4; Q5TCU7; Q9UH67


The Tropomyosin beta chain, also known as Beta-tropomyosin or Tropomyosin-2, is a crucial protein that binds to actin filaments in both muscle and non-muscle cells. It plays a pivotal role in the calcium-dependent regulation of vertebrate striated muscle contraction, in association with the troponin complex. Additionally, it is involved in smooth muscle contraction regulation through interaction with caldesmon and stabilizes cytoskeleton actin filaments in non-muscle cells.

Therapeutic significance:

The Tropomyosin beta chain is implicated in several muscular disorders, including Nemaline myopathy 4, Distal arthrogryposis types 1A and 2B4, and Cap myopathy 2. These conditions highlight the protein's critical role in muscle function and development. Understanding the role of Tropomyosin beta chain could open doors to potential therapeutic strategies for these debilitating diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.